Tom Daniel, MD
Venture Partner, Arch Venture Partners
Chairman of the Board
Tom Daniel led Global Research and Early Development at Celgene Corporation over a decade, as the company emerged as a leader in defining new mechanisms for drug action, established industry leading collaborative networks, and discovered, advanced and commercialized innovative medicines in oncology and inflammatory diseases. He previously served as Chief Scientific Officer and Director of AmbRx, as Vice President of Research at Amgen, and as Senior Vice President of Discovery Research at Immunex Corporation.
Tom is currently Chairman at Vividion Therapeutics, director at VIR Bio, Magenta Therapeutics, Gossamer Bio, ImmunsanT, Sana Therapeutics and Zafgen, Inc. He is a venture partner at Arch Venture Partners, a Trustee of Reed College, serves on the Board of the Lupus Research Alliance, Chairs the Board of Overseers of The Scripps Research Institute, and serves on the Biomedical Science Advisory Board of Vanderbilt University Medical Center and on the Parker Institute for Cancer Immunotherapy. A nephrologist and former academic investigator, Tom was previously Hakim Professor of Medicine and Cell Biology at Vanderbilt. He earned his medical degree from UT Southwestern, completed medical residency at Massachusetts General Hospital, and trained in molecular genetics at UTSW.